Felixvet Introduces Clomipramine Hydrochloride Tablets for the Treatment of Separation Anxiety in Dogs

Kansas City, Mo. — July 9, 2026 — Felixvet Inc. today announced the commercial availability of Clomipramine Hydrochloride Tablets, an FDA-approved treatment indicated for separation anxiety in dogs greater than six months of age when used as part of a comprehensive behavioral management program. Approved by the U.S. Food and Drug Administration (FDA) on October 21, 2025, Clomipramine Hydrochloride Tablets are therapeutically equivalent to the pioneer product and provide veterinarians with a trusted treatment option for managing one of the most common behavioral conditions seen in companion animal practice.

Product Details

“Behavioral health is an important part of overall animal health, and separation anxiety remains one of the most common challenges veterinarians help pet owners address,” said Lauren Landolph, Vice President, Commercial Strategy & Distribution Channels, Felixvet. “We’re excited to bring Clomipramine Hydrochloride Tablets to market and provide veterinarians with another FDA-approved treatment option that can help improve outcomes for both dogs and their families.”

Clomipramine Hydrochloride Tablets are indicated for use as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than six months of age and are intended to be used in conjunction with behavior modification techniques.

Felixvet’s Clomipramine Hydrochloride Tablets are available in:

• 5 mg tablets 
• 20 mg tablets 
• 40 mg tablets 
• 80 mg tablets 

All strengths are supplied in 30-count bottles and are formulated for oral administration in dogs. The product is therapeutically equivalent to the pioneer drug and offers the same safety and efficacy profile.

Felixvet continues to expand its portfolio of FDA-approved companion animal pharmaceuticals, supporting veterinarians and distribution partners with high-quality, bioequivalent treatment options across key therapeutic categories.

For additional information, please contact info@felixvet.com

About Felixvet

Founded in 2015 by Dr. Shumeet Banerji, Jon Symonds and Neeraj Agrawal, Felix develops and commercializes high-quality, bioequivalent pharmaceutical products for companion animals. The company is focused on expanding access to FDA-approved veterinary medicines through a growing portfolio of trusted treatment options for veterinarians and pet owners.

Media Contact

Paula Flavin
Project Marketing Manager, US Operations
D: 816-912-2000
E: info@felixvet.com